Mihir Kanitkar, MD
Interventional Cardiology · Huntsville, ALNPI 1487831566
Payments from drug & device makers
What this record shows
Edwards Lifesciences accounts for 62.7% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2019 at $2,721 and has fallen 94.9% since, to $138 in 2025. That places this record below the midpoint for interventional cardiology clinicians in AL, where the typical reported total is $6,630.
Across 126 payments — averaging $56.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$4K
- Boston Scientific$905
- Abbott$647
- Johnson & Johnson$250
- Amgen$140
- Novartis$124
- plus $570 from 13 others
Across 34 payments — averaging $11,384 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$359K
- Abbott$28K
What the payments were for
- Travel & lodging$3,60451%
- Food & beverage$3,46449%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 25 | $4,433 |
| Boston Scientific | 13 | $905 |
| Abbott | 19 | $647 |
| Johnson & Johnson | 18 | $250 |
| Amgen | 9 | $140 |
| Novartis | 6 | $124 |
| Pfizer | 6 | $120 |
| AstraZeneca | 7 | $100 |
| Cardiovascular Systems Inc. | 5 | $59 |
| Medtronic(2 entities) | 4 | $55 |
| W. L. Gore & Associates, Inc. | 1 | $45 |
| Regeneron Healthcare Solutions, Inc. | 3 | $39 |
| Sanofi-aventis U.S. LLC | 2 | $33 |
| E.r. Squibb & Sons, L.L.C. | 2 | $32 |
| Philips North America LLC | 2 | $24 |
| Siemens Medical Solutions USA, Inc. | 1 | $18 |
| Scpharmaceuticals Inc. | 1 | $17 |
| Abiomed | 1 | $15 |
| Boehringer Ingelheim | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,069 in reported general payments places this provider in the 50th percentile of 109 interventional cardiology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 347 | $304,874 |
| EntrestoSacubitril/Valsartan | 104 | $109,715 |
| XareltoRivaroxaban | 59 | $69,010 |
| JardianceEmpagliflozin | 43 | $45,420 |
| Repatha SureclickEvolocumab | 64 | $43,739 |
| FarxigaDapagliflozin Propanediol | 21 | $19,032 |
| BrilintaTicagrelor | 32 | $18,031 |
| Metoprolol Succinate | 399 | $8,152 |
| Ranolazine ErRanolazine | 74 | $6,626 |
| Praluent PenAlirocumab | 14 | $6,356 |
| Prasugrel Hcl | 80 | $4,049 |
| Atorvastatin Calcium | 257 | $3,957 |
| Icosapent Ethyl | 12 | $3,189 |
| Carvedilol | 288 | $2,652 |
| ClopidogrelClopidogrel Bisulfate | 140 | $1,716 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $120 | $304,874347 claims |
| NovartisEntresto | $124 | $109,715104 claims |
| Johnson & JohnsonXarelto | $250 | $69,01059 claims |
| Boehringer IngelheimJardiance | $12 | $45,42043 claims |
| AstraZenecaFarxiga, Brilinta | $100 | $37,06353 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 109 interventional cardiology providers in Alabama.
Other interventional cardiology in Huntsville
- Michael ButlerHuntsville$109K
- Pochana ReddyHuntsville$100K
- Alejandro VasquezHuntsville$45K
- David DrenningHuntsville$31K
- Clarence GillHuntsville$13K
- Victor OkunrintemiHuntsville$12K
- Henry ChenHuntsville$8K
- Gary RoubinBirmingham$157K
- Robert FosterBirmingham$90K
- Hasan GuvenBirmingham$86K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.